Buspirone transdermal - Acrux

Drug Profile

Buspirone transdermal - Acrux

Alternative Names: Buspirone MDTS®

Latest Information Update: 14 Jun 2007

Price : $50

At a glance

  • Originator Acrux
  • Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Fibromyalgia

Most Recent Events

  • 22 Aug 2005 Phase I trials have been completed for Anxiety disorders and Fibromyalgia; further development will continue once a partnership agreement has been secured
  • 07 Mar 2005 Phase-I clinical trials in Fibromyalgia in Australia (Transdermal)
  • 02 Jul 2004 Phase-I clinical trials in Anxiety disorders in Australia (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top